Avant Technologies Inc., a Nevada-based corporation, and Singapore-based biotechnology firm SGAustria Pte. Ltd. have announced a Joint Venture and License Agreement to pioneer next-generation diabetes treatments using stem cell and encapsulation technologies.
The partnership aims to advance a proprietary differentiation process that transforms stem cells into insulin-producing and regulating cells, forming the foundation for a potential therapy targeting type 1 and insulin-dependent type 2 diabetes.
Through this collaboration, Avant and SGAustria plan to integrate stem cell expertise with SGAustria’s encapsulation platform to develop safe, potent, and scalable therapeutic solutions. The venture will also establish a new U.S.-based company, Insulinova, Inc., to oversee upcoming clinical trials.
“We’re thrilled to join forces with SGAustria in this game-changing Joint Venture,” said Chris Winter, CEO of Avant Technologies. “By merging our capital and strategic vision with their biotech innovations, we’re setting the stage for revolutionary diabetes therapies that could transform countless lives.”
Under the agreement, SGAustria will contribute its clinically proven cell-encapsulation technology, which enables the protection, storage, and transport of living cells. With over 50 peer-reviewed publications and collaborations with major biotech firms, SGAustria brings strong expertise in GMP-grade manufacturing and cell biology.
Avant Technologies will provide initial funding over the next eight months to meet development milestones and secure additional financing for a planned Phase 1 clinical trial in the U.S. or an equivalent region.
“SGAustria’s encapsulation platform holds tremendous promise for reshaping cell therapies,” said Brian Salmons, CEO of SGAustria. “This Joint Venture reflects our shared commitment to advancing reliable, cutting-edge treatments for diabetes.”
The new alliance, once fully realized, could mark a major step forward in regenerative medicine, offering innovative treatment options for millions living with diabetes worldwide.